

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**TONGOUR SIMPSON HOLSCRAW LYTTLE, LLC**

2. Address:

227 MASSACHUSETTS AVE NE #1, WASHINGTON, DC 20002

3. Principal place of business (if different from line 2):

4. Contact Name: JOHN BRAD HOLSCRAW

Telephone: 202-544-7600

E-mail (optional): HOLSCRAW@tongoursimpson.com

Senate ID #: 51478-75

House ID #: 34927003

7. Client Name:  Self

**AVENTIS PHARMACEUTICALS INC**

### TYPE OF REPORT

8. Year 2001 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 60,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: TONGOUR SIMPSON HOLSCLOW LYTLE, LLC Client Name: AVENTIS  
PHARMACEUTICALS INC  
**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

1) H.R. 2330 and S.1119, FY 2002 AG Appropriations specifically provisions relating to the re-importation of prescription drugs. 2) Prescription drug coverage for Medicare beneficiaries. 3) S. 826, Improved Access to Osteoporosis Testing Act.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HOLSCLOW, JOHN BRAD

Covered Official Position (if applicable): N/A

Name: TONGOUR, MICHAEL

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Aventis Pharmaceuticals, Inc. is wholly owned by Aventis Pharma AG headquartered in Frankfurt, Germany. This is a pharmaceutical company which is owned by Aventis S.A. with global headquarters in Strasbourg, France. Both companies' business interests would be affected by the issues in line 16.

Signature: ON FILE Date: Aug 08, 2001

Printed Name and Title: JOHN BRAD HOLSCLOW - PARTNER